ClinicalTrials.gg

Program

Dabigatran

Also written as “Dabigatran etexilate”, “dabigatran etexilate” and “Dabigatran Etexilate”.

Its studies are mostly in Venous Thromboembolism · Atrial Fibrillation · Thromboembolism · Thrombosis · Renal Insufficiency, led by 3 companies.

Furthest: phase 4, since Aug 16, 201077 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim740 open or runningphase 4since Aug 16, 2010Sep 8, 2005none ahead
Merck20 open or runningphase 1since Jun 3, 2011Jun 3, 2011none ahead
Merck KGaA, Darmstadt, Germany10 open or runningphase 1since Apr 3, 2018Apr 3, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 15 studies since Oct 20, 2010.

  1. Jun 20, 201431 phase 1 studiesBoehringer Ingelheim · NCT02173717, NCT02171624, NCT02171611 and 28 more
  2. Jun 20, 20142 phase 2 studies in Venous ThromboembolismBoehringer Ingelheim · NCT02170935, NCT02170701
  3. Jul 2, 2014Phase 1 study in Renal InsufficiencyBoehringer Ingelheim · NCT02182024 · 35 enrolled
  4. Jul 21, 2014Phase 3 study in Venous ThromboembolismBoehringer Ingelheim · NCT02197416 · 214 enrolled · United States, Austria, Belgium and more
  5. Aug 21, 2014Phase 2 study in Venous ThromboembolismBoehringer Ingelheim · NCT02223260 · 8 enrolled · Canada, France, Russian Federation
  6. Sep 10, 2014Phase 3 study in StrokeBoehringer Ingelheim · NCT02239120 · 5,390 enrolled · United States, Argentina, Australia and more
  7. Jan 27, 2015Phase 4 study in Atrial FibrillationBoehringer Ingelheim · NCT02348723 · 678 enrolled · United States, Belgium, Canada and more
  8. Sep 21, 2016Phase 3 study in ThromboembolismBoehringer Ingelheim · NCT02913326 · 120 enrolled · France, Germany, India and more
  9. Feb 28, 2017Phase 1 study in HealthyBoehringer Ingelheim · NCT03070171 · 160 enrolled · Japan
  10. Mar 16, 2017Phase 1 study in Healthy VolunteersBoehringer Ingelheim · NCT03086356 · 12 enrolled · China
  11. May 4, 2017Phase 1 study in Non-alcoholic Fatty Liver DiseaseBoehringer Ingelheim · NCT03143166 · 36 enrolled · Japan
  12. Oct 12, 2017Phase 1 study in Renal InsufficiencyMerck · NCT03311841 · 32 enrolled · United States
  13. Apr 3, 2018Merck KGaA, Darmstadt, Germany's first study: phase 1 study in Carcinoma, Non-Small-Cell LungNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT03492437 · 20 enrolled · Germany
  14. Feb 4, 2020Phase 1 study in HealthyBoehringer Ingelheim · NCT04257032 · 28 enrolled · Germany

TargetBeta

F2 →read by rule
“Thrombin inhibitor”ChEMBL 37, by rule

Studies

The newest 60 of 77 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT04257032Healthy · Germany1CompletedBoehringer IngelheimSep 23, 202028
NCT03492437Carcinoma, Non-Small-Cell Lung · Germany1CompletedMerck KGaA, Darmstadt, GermanyAug 27, 201820
NCT03311841Renal Insufficiency · United States1CompletedMerckAug 2, 201832
NCT03143166Non-alcoholic Fatty Liver Disease · Japan1CompletedBoehringer IngelheimJul 27, 201736
NCT03086356Healthy Volunteers · China1CompletedBoehringer IngelheimSep 12, 201712
NCT03070171Healthy · Japan1CompletedBoehringer IngelheimJun 16, 2017160
NCT02913326Thromboembolism · France, Germany, India and more3CompletedBoehringer IngelheimJun 22, 2018120
NCT02348723Atrial Fibrillation · United States, Belgium, Canada and more4CompletedBoehringer IngelheimNov 11, 2016678
NCT02239120Stroke · United States, Argentina, Australia and more3CompletedBoehringer IngelheimAug 14, 20185,390
NCT02223260Venous Thromboembolism · Canada, France, Russian Federation2CompletedBoehringer IngelheimJan 20168
NCT02197416Venous Thromboembolism · United States, Austria, Belgium and more3CompletedBoehringer IngelheimOct 16, 2019214
NCT02182024Renal Insufficiency1CompletedBoehringer IngelheimMar 200635
NCT02173717Healthy1CompletedBoehringer IngelheimJul 200924
NCT02171624Healthy1CompletedBoehringer IngelheimApr 200942
NCT02171611Healthy1CompletedBoehringer IngelheimMay 200930
NCT02171598Healthy1CompletedBoehringer IngelheimJul 200944
NCT02171585Healthy1CompletedBoehringer IngelheimAug 200820
NCT02171546Healthy1TerminatedBoehringer IngelheimJan 200842
NCT02171533Healthy1CompletedBoehringer IngelheimAug 200840
NCT02171507Healthy1CompletedBoehringer IngelheimJul 200624
NCT02171468Healthy1CompletedBoehringer IngelheimJul 200648
NCT02171455Healthy1CompletedBoehringer IngelheimJan 200610
NCT02171052Healthy1CompletedBoehringer IngelheimAug 200624
NCT02171039Healthy1CompletedBoehringer IngelheimAug 200624
NCT02171026Healthy1CompletedBoehringer IngelheimJun 200624
NCT02171000Healthy1CompletedBoehringer IngelheimMay 20057
NCT02170974Healthy1CompletedBoehringer IngelheimAug 200428
NCT02170935Venous Thromboembolism2CompletedBoehringer IngelheimJun 200262
NCT02170922Healthy1CompletedBoehringer IngelheimAug 19996
NCT02170909Healthy1CompletedBoehringer IngelheimJun 200542
NCT02170896Healthy1CompletedBoehringer IngelheimDec 200116
NCT02170844Healthy1CompletedBoehringer IngelheimAug 200440
NCT02170831Healthy1CompletedBoehringer IngelheimJul 199940
NCT02170792Healthy1CompletedBoehringer IngelheimMar 200130
NCT02170766Healthy1CompletedBoehringer IngelheimDec 200048
NCT02170740Healthy1CompletedBoehringer IngelheimJan 200026
NCT02170701Venous Thromboembolism2CompletedBoehringer IngelheimJun 2001289
NCT02170675Healthy1CompletedBoehringer IngelheimJul 200924
NCT02170636Healthy1CompletedBoehringer IngelheimMar 200215
NCT02170623Healthy1CompletedBoehringer IngelheimApr 200212
NCT02170610Healthy1CompletedBoehringer IngelheimMay 200218
NCT02170597Healthy1CompletedBoehringer IngelheimSep 200312
NCT02170584Healthy1CompletedBoehringer IngelheimMar 200130
NCT02170571Hepatic Insufficiency1CompletedBoehringer IngelheimDec 200524
NCT02170116Healthy1CompletedBoehringer IngelheimDec 199840
NCT02164864Atrial Fibrillation · United States, Argentina, Australia and more3CompletedBoehringer IngelheimJun 5, 20172,725
NCT02044367Healthy · Germany1CompletedBoehringer IngelheimApr 201454
NCT01896297Atrial Fibrillation · United States4CompletedBoehringer IngelheimOct 201563
NCT01895777Venous Thromboembolism · United States, Argentina, Austria and more3CompletedBoehringer IngelheimOct 16, 2019267
NCT01773174Venous Thromboembolism · United States2WithdrawnBoehringer IngelheimDec 20150
NCT01711853Renal Insufficiency, Chronic · Netherlands1CompletedBoehringer IngelheimDec 201319
NCT01505881Thromboembolism · Belgium, Canada, Czech Republic and more2TerminatedBoehringer IngelheimJun 2013158
NCT01493557Atrial Fibrillation · United States, Canada4CompletedBoehringer IngelheimJul 20141,067
NCT01452347Heart Valve Diseases · Belgium, Canada, Czech Republic and more2TerminatedBoehringer IngelheimJun 2013328
NCT01379300Thrombosis1CompletedMerckDec 201142
NCT01306162Healthy · Germany1CompletedBoehringer IngelheimMay 201136
NCT01290757Healthy · Germany1CompletedBoehringer IngelheimApr 2011180
NCT01241539Cardiovascular Diseases · Germany1CompletedBoehringer IngelheimMay 20117
NCT01227629Atrial Fibrillation · United States, Denmark, Sweden2CompletedBoehringer IngelheimNov 2004502
NCT01225822Venous Thromboembolism · Austria, Belgium, Czech Republic and more2CompletedBoehringer IngelheimAug 20031,973

How it is read

Names in the registry

  • “Dabigatran etexilate”, 27 entries
  • “dabigatran etexilate”, 21 entries
  • “Dabigatran”, 7 entries
  • “Dabigatran Etexilate”, 6 entries
  • “dabigatran with ASA”, 6 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.